Telos Capital Management’s VanEck Pharmaceutical ETF PPH Stock Holding History

Telos Capital Management’s Portfolio PPH Stock Details PPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$611K	Sell	5,592 -379	-6%	-$39.2K	0.05%	140
2026 Q1	$620K	Sell	5,971 -286	-5%	-$30.5K	0.06%	138
2025 Q4	$646K	Buy	6,257 +15	+0.2%	+$1.46K	0.06%	140
2025 Q3	$564K	Buy	6,242 +1,726	+38%	+$151K	0.05%	142
2025 Q2	$397K	Buy	4,516 +92	+2%	+$7.97K	0.04%	159
2025 Q1	$403K	Sell	4,424 -27	-0.6%	-$2.43K	0.04%	153
2024 Q4	$384K	Buy	+4,451	New	+$403K	0.04%	159

Other funds holding PPH

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

JSAM

J. Safra Asset Management New York $2.17B AUM 29.66% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Avalon Trust Santa Fe, New Mexico $1.63B AUM 42.75% 1-Year Est. Return

AWC

Adamsbrown Wealth Consultants Wichita, Kansas $530M AUM 23.21% 1-Year Est. Return

Telos Capital Management's PPH Position: Q2 2026 in Review

Telos Capital Management reduced its VanEck Pharmaceutical ETF (PPH) stake by 6.3% in Q2 2026, selling an estimated $39.2K and leaving 5,592 shares worth $611K. The position accounts for 0.05% of the portfolio, ranked #140.

Telos Capital Management first reported a position in PPH in Q4 2024 and has held it in 7 quarters since. The position peaked at $646K in Q4 2025. 147 funds tracked by Wall St. Rank hold PPH as of Q2 2026.

Telos Capital Management held 5,592 shares of VanEck Pharmaceutical ETF worth $611K as of Q2 2026.
Telos Capital Management sold 379 VanEck Pharmaceutical ETF shares in Q2 2026, an estimated $39.2K.
VanEck Pharmaceutical ETF made up 0.05% of Telos Capital Management's portfolio in Q2 2026, its #140 holding.
Telos Capital Management first reported a position in VanEck Pharmaceutical ETF in Q4 2024 and has held it in 7 quarters since.
Telos Capital Management's VanEck Pharmaceutical ETF position peaked at $646K in Q4 2025.
147 funds tracked by Wall St. Rank held VanEck Pharmaceutical ETF as of Q2 2026.

Based on Telos Capital Management's 13F filing for Q2 2026, filed 22 Jul 2026.